Results 1 to 10 of about 3,203,567 (223)

Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study. [PDF]

BMC Neurol, 2015
BackgroundTo understand the current state of insufficient drug efficacy experienced by patients with Parkinson’s disease (PD) and its effects on quality of life (QOL), we conducted a survey of patients with PD and analyzed the results from 2,630 ...
Tsugawa J, Onozawa R, Fukae J, Mishima T, Fujioka S, Tsuboi Y.   +5 more
europepmc   +4 more sources

Sustained release antiparkinson agents: controlled release levodopa. [PDF]

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1992
ABSTRACT:The rationale for sustained release oral levodopa preparations is to deliver levodopa in the areas of maximal intestinal absorption in a slow and predictable way, leading to stable plasma levodopa levels and brain dopamine levels, therefore resulting in a lengthened duration of action.
Serge Gauthier, Donna Amyot
semanticscholar   +6 more sources

2. Neuromuscular Disorders due to Adverse Effects of Antiparkinson Agents

Nihon Naika Gakkai Zasshi, 2007
Nobutaka Hattori
semanticscholar   +6 more sources

Anticonvulsant Activity of Antiparkinsonism Agents

Experimental Biology and Medicine, 1968
SummaryThe anticonvulsant activity of synthetic antiparkinsonism agents has been studied in mice with experimental seizures and in children with myoclonic spasms refractory to conventional medications. Procyclidine and trihexyphenidyl protected mice from maximal electroshock seizures.
J Gordon Millichap, G. L. Pitchford, M. G. Millichap   +2 more
openalex   +4 more sources

Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

, 2017
Background: Parkinson disease (PD) generally requires therapy for prolonged periods often with multiple drugs; drug-related adverse effects often add to the existing morbidity.
Firoz Thaha, Reneega Gangadhar, Thomas Iype, Reeja Rajan   +3 more
openalex   +3 more sources

Exploiting second-order advantage from mathematically modeled voltammetric data for simultaneous determination of multiple antiparkinson agents in the presence of uncalibrated interference [PDF]

Journal of the Taiwan Institute of Chemical Engineers / Elsevier, 2018
Ghobad Mohammadi, Khodabakhsh Rashidi, Majid Mahmoudi, Héctor C. Goicoechea, Ali R. Jalalvand   +4 more
openalex   +2 more sources

COMPARISON OF THE ELECTROENCEPHALOGRAPHIC AND MOTOR EFFECTS OF ORPHENADRINE, AN ANTIPARKINSON AGENT

Japanese Journal of Pharmacology, 1968
Takashi Ban, Masakazu Hojo
openalex   +5 more sources

Drug interaction (19. combination with antiparkinson agents)

, 2010
Satoru Ezumi, Satoshi Kuroda, Hisashi Matsunaga, Toshiaki Sendo   +3 more
openalex   +3 more sources

Characteristic action of BAM-1110, a new antiparkinson agent, on dopamine receptors

Japanese Journal of Pharmacology, 1997
Kenit Ichihara, Hiroyuki Kamei, Keiichi Okumura, Mitsuaki Nagasaka   +3 more
openalex   +3 more sources

Validation of 19-items wearing-off (WOQ-19) questionnaire to Portuguese [PDF]

Arquivos de Neuro-Psiquiatria, 2020
Background: The treatment of Parkinson disease with dopaminergic therapy improves functionality and quality of life. However, as the disease progresses, the wearing-off phenomenon develops.
Carlos Eduardo MANTESE, Marcio MEDEIROS, Artur SCHUMACHER-SCHUH, Carlos Roberto de Melo RIEDER   +3 more
doaj   +1 more source